ArticleFrontiers in medicine2026

Three-year longitudinal assessment of denosumab's efficacy and safety in postmenopausal osteoporosis: a 36-month real-world cohort study.

Rong-Lin Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.